UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                November 18, 2004
                                -----------------
                Date of Report (Date of earliest event reported)

                            OSI PHARMACEUTICALS, INC.
                            -------------------------
             (Exact name of registrant as specified in its charter)


           DELAWARE                      0-15190                 13-3159796
           --------                      -------               --------------
(State or other jurisdiction of        (Commission            (I.R.S. Employer
       incorporation)                  File Number)          Identification No.)


                              58 SOUTH SERVICE ROAD
                               MELVILLE, NY 11747
                          ----------------------------
                    (Address of principal executive offices)

                                 (631) 962-2000
                            ------------------------
              (Registrant's telephone number, including area code)

                                      N/A
                              --------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a- 12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






ITEM 8.01  OTHER EVENTS

         On November 19, 2004, OSI Pharmaceuticals, Inc. (the "Company") issued
a press release relating to the Food and Drug Administration's approval of
Tarceva(TM) for patients with advanced non-smallcell lung cancer. The Company's
press release is attached to this Current Report as Exhibit 99.1 and is
incorporated by reference herein.






                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: November 19, 2004                    OSI PHARMACEUTICALS, INC.


                                      By:  /s/ Robert L. Van Nostrand
                                           -------------------------------------
                                           Robert L. Van Nostrand
                                           Vice President and Chief Financial
                                           Officer (Principal Financial Officer)



                                       3